Who should participate?
The LEO Pharma Open Innovation platform is basically open for any official institution or registered company with compounds, such as (but not limited to):
SMEs/Biotech companies – could be early compounds with relevant in vitro and/or in vivo results that could be of interest to LEO Pharma for e.g. in-licensing or collaborative drug discovery.
Research institutions – e.g. government or foundation sponsored research developing compounds for e.g. pharmacological explorations and target evaluation.
University groups – e.g. University department with compounds holding unique properties, both for pursuing concept and novel treatments.
Pharmaceutical companies – compound assets that could be out-licenced with a dermatological and skin inflammatory focus.